Shorla Pharma seeks FDA approval for oncology drug
Shorla Pharma seeks FDA approval for oncology drug The SH-111 drug will have a significant benefit, particularly for children with leukemia about 3 hours ago Tipperary-based company Shorla Pharma has filed an application with the US Food and Drug Administration (FDA) to bring its specialty oncology drug designed to treat T-cell leukemia to market later this year. The SH-111 drug is a lifesaving treatment that is often in shortage. “We’re very proud that SH-111 will have a significant clinical benefit particularly for children with leukemia,” said Sharon Cunningham, CEO and Co-founde...